Skip navigation
Skip navigation

Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma

Gargett, T.; Abbas, M. N.; Rolan, P.; Price, Jason D.; Gosling, Katharine M.; Ferrante, A.; Ruszkiewicz, A.; Atmosukarto, Ines I. C.; Altin, Joseph; Parish, Christopher; Brown, M. P.


INTRODUCTION: In this phase I study using a 3 + 3 dose escalation design, the safety, dose-limiting toxicity (DLT), immunogenicity and efficacy of intravenous Lipovaxin-MM-a multi-component dendritic cell-targeted liposomal vaccine against metastatic melanoma-was investigated. METHODS: Twelve subjects with metastatic cutaneous melanoma were recruited in three cohorts. Patients in Cohort A (n = 3) and Cohort B (n = 3) received three doses of 0.1 and 1 mL of Lipovaxin-MM, respectively,...[Show more]

CollectionsANU Research Publications
Date published: 2018
Type: Journal article
Source: Cancer Immunology, Immunotherapy
DOI: 10.1007/s00262-018-2207-z


File Description SizeFormat Image
01_Gargett_Phase_I_trial_of_Lipovaxin-MM%2C_2018.pdf1.5 MBAdobe PDF    Request a copy

Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  19 May 2020/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator